{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/anticoagulation-oral/","result":{"data":{"firstChapter":{"id":"b5dcda3e-cc4c-56b5-9348-00f8e8eb8e32","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 97c8ac52-9f6d-4b7c-a5c9-95cdae93cd9e --><h1>Anticoagulation - oral: Summary</h1><!-- end field 97c8ac52-9f6d-4b7c-a5c9-95cdae93cd9e -->","htmlStringContent":"<!-- begin item ef246386-4fd2-4c4c-9048-29d4b4d2ec63 --><!-- begin field ad2354d8-b47f-43b5-b8e1-193471a7e332 --><ul><li>There are two main types of oral anticoagulants: vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs).<ul><li>Warfarin, the most commonly used VKA, is a coumarin derivative that acts by inhibiting vitamin K dependent clotting factors (II, VII, IX, X) in addition to the anticoagulant proteins C and S. Warfarin has been used for decades as an anticoagulant.</li><li>DOACS (apixaban, dabigatran, edoxaban, and rivaroxaban) are anticoagulants with a novel mode of action: apixaban, edoxaban, and rivaroxaban are direct and reversible inhibitors of factor Xa (inhibition of factor Xa prevents thrombin generation and thrombus development). Dabigatran is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation.</li></ul></li><li>Warfarin is licensed for prophylaxis of embolization in rheumatic heart disease and atrial fibrillation, prophylaxis after insertion of prosthetic heart valve, prophylaxis and treatment of venous thrombosis and pulmonary embolism (PE), and transient ischaemic attacks.</li><li>Apixaban, dabigatran, edoxaban, and rivaroxaban may be prescribed instead of warfarin for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and at least one risk factor, such as heart failure, hypertension, previous stroke or transient ischaemic attack, age 75 years or older, or diabetes mellitus. In addition:<ul><li style=\"box-sizing: inherit;\">Apixaban, dabigatran, edoxaban, and rivaroxaban are licensed for the treatment of PE and deep vein thrombosis (DVT), and prevention of recurrent DVT and PE.</li><li style=\"box-sizing: inherit;\">Apixaban, dabigatran, and rivaroxaban are licensed for the prophylaxis of venous thromboembolism after elective hip or knee replacement surgery.</li><li style=\"box-sizing: inherit;\">Rivaroxaban is licensed for prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel) and for prophylaxis of atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events (in combination with aspirin).</li></ul></li><li>The most common adverse effect of anticoagulants is bleeding.<ul><li>Warfarin, apixaban, dabigatran, and rivaroxaban have antidotes for reversing their anticoagulant effects. There is currently no antidote for edoxaban. </li></ul></li><li>Unlike warfarin, DOACs do not require regular international normalized ratio (INR) monitoring. However, regular follow up is required to review the treatment, assess for adverse effects (such as bleeding), assess for thromboembolic events, and provide appropriate information and advice.</li></ul><!-- end field ad2354d8-b47f-43b5-b8e1-193471a7e332 --><!-- end item ef246386-4fd2-4c4c-9048-29d4b4d2ec63 -->","topic":{"id":"5e046307-14e1-50a6-9729-69af5ae00b78","topicId":"d64523b7-19f2-41a0-afd4-d1c0790cce30","topicName":"Anticoagulation - oral ","slug":"anticoagulation-oral","aliases":[],"chapters":[{"id":"b5dcda3e-cc4c-56b5-9348-00f8e8eb8e32","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"2424a367-7b32-59ea-8783-9d80a1a68c3c","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"02a83663-a0e4-533a-a0a3-a6b15235867c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"31157a72-4e11-5ad4-8139-919ce4241f22","slug":"changes","fullItemName":"Changes"},{"id":"14f1139a-434d-530b-be52-9692e9271a76","slug":"update","fullItemName":"Update"}]},{"id":"67dfc47b-2285-596f-9f26-279a85f25dcc","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"a4b943e8-803b-51b4-a154-3a58c4bbaf1a","slug":"goals","fullItemName":"Goals"},{"id":"1a8fff43-5d5a-5e06-803b-ea61542c56a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a1c4ef1a-272a-56c2-bba9-b437e8b0e03d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"54bcfbdc-7506-5ca1-ae0c-e5ab55acb001","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2387aba8-f14a-5fc6-8335-485e08a6c959","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"dd9aca34-523a-570a-bb3f-422e7bf450a7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"e9b14f86-2066-57e8-9b9f-65926e978b59","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"55f43edd-e0fd-5e66-a53b-36ef8f137cd3","slug":"licensed-indications","fullItemName":"Licensed indications"}]},{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","slug":"management","fullItemName":"Management","subChapters":[{"id":"46bb380b-6d51-5ede-b5dc-78ec7987f404","slug":"apixaban","fullItemName":"Scenario: Apixaban"},{"id":"e4a2d921-e87f-5760-a17a-271fefa9d1c4","slug":"dabigatran","fullItemName":"Scenario: Dabigatran"},{"id":"e0aace92-5b9a-53c2-af09-6318f0911654","slug":"edoxaban","fullItemName":"Scenario: Edoxaban"},{"id":"015cbcc5-4efe-568f-9643-d7a22d37b286","slug":"rivaroxaban","fullItemName":"Scenario: Rivaroxaban"},{"id":"693e35a4-4b44-514c-847c-855a53793f98","slug":"warfarin","fullItemName":"Scenario: Warfarin"}]},{"id":"3d346e04-bfd5-53aa-9cbe-bee5c6a912bb","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"76dbe1dd-0d3b-50e8-9472-5af55550c77a","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"5f762de3-78b6-55d7-b9bb-cc3f1cb77bea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c725a38-4d35-5fbd-bd5d-b48afc70e783","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2b9eb7d5-9bc8-5af8-b91f-75e9b1480d83","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33630559-9216-56bf-9890-6bbe997245bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51bd3b51-3e20-5f51-a925-74b2c904fd53","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"54dbb8de-8bee-5c53-b63b-9645b55e6b5d","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"5e046307-14e1-50a6-9729-69af5ae00b78","topicId":"d64523b7-19f2-41a0-afd4-d1c0790cce30","topicName":"Anticoagulation - oral ","slug":"anticoagulation-oral","aliases":[],"topicSummary":"There are five oral anticoagulants licensed for use in the UK: warfarin, apixaban, dabigatran, edoxaban and rivaroxaban.","lastRevised":"January 2021","nextPlannedReviewBy":"2026-01-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2026-01","nextPlannedReviewByDisplay":"January 2026","specialities":[{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"},{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"},{"id":"ef40c5ff-41df-5fad-804e-7629896151bb","name":"Haematology","slug":"haematology"},{"id":"2454765b-1b2d-53fc-b288-17b66486f41a","name":"Preventative medicine","slug":"preventative-medicine"}],"chapters":[{"id":"b5dcda3e-cc4c-56b5-9348-00f8e8eb8e32","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"2424a367-7b32-59ea-8783-9d80a1a68c3c","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"02a83663-a0e4-533a-a0a3-a6b15235867c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"31157a72-4e11-5ad4-8139-919ce4241f22","slug":"changes","fullItemName":"Changes"},{"id":"14f1139a-434d-530b-be52-9692e9271a76","slug":"update","fullItemName":"Update"}]},{"id":"67dfc47b-2285-596f-9f26-279a85f25dcc","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"a4b943e8-803b-51b4-a154-3a58c4bbaf1a","slug":"goals","fullItemName":"Goals"},{"id":"1a8fff43-5d5a-5e06-803b-ea61542c56a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a1c4ef1a-272a-56c2-bba9-b437e8b0e03d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"54bcfbdc-7506-5ca1-ae0c-e5ab55acb001","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2387aba8-f14a-5fc6-8335-485e08a6c959","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"dd9aca34-523a-570a-bb3f-422e7bf450a7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"e9b14f86-2066-57e8-9b9f-65926e978b59","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"55f43edd-e0fd-5e66-a53b-36ef8f137cd3","slug":"licensed-indications","fullItemName":"Licensed indications"}]},{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","slug":"management","fullItemName":"Management","subChapters":[{"id":"46bb380b-6d51-5ede-b5dc-78ec7987f404","slug":"apixaban","fullItemName":"Scenario: Apixaban"},{"id":"e4a2d921-e87f-5760-a17a-271fefa9d1c4","slug":"dabigatran","fullItemName":"Scenario: Dabigatran"},{"id":"e0aace92-5b9a-53c2-af09-6318f0911654","slug":"edoxaban","fullItemName":"Scenario: Edoxaban"},{"id":"015cbcc5-4efe-568f-9643-d7a22d37b286","slug":"rivaroxaban","fullItemName":"Scenario: Rivaroxaban"},{"id":"693e35a4-4b44-514c-847c-855a53793f98","slug":"warfarin","fullItemName":"Scenario: Warfarin"}]},{"id":"3d346e04-bfd5-53aa-9cbe-bee5c6a912bb","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"76dbe1dd-0d3b-50e8-9472-5af55550c77a","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"5f762de3-78b6-55d7-b9bb-cc3f1cb77bea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c725a38-4d35-5fbd-bd5d-b48afc70e783","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2b9eb7d5-9bc8-5af8-b91f-75e9b1480d83","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33630559-9216-56bf-9890-6bbe997245bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51bd3b51-3e20-5f51-a925-74b2c904fd53","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"54dbb8de-8bee-5c53-b63b-9645b55e6b5d","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"5e046307-14e1-50a6-9729-69af5ae00b78"}},"staticQueryHashes":["3666801979"]}